Gothenburg

• A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Efficacy and Safety of Dirocaftor/Posenacaftor/ … Not authorised
  2022-500410-26-00 5 Cystic Fibrosis
• Early intervention and recovery of sexual function in men and women after treatment of rectal cancer–a randomized placebo-controlled study w … Pending
  2023-504592-24-00 4 sexual/ erectile function in women and men after treatment for rectal
• IntReALL BCP 2020 – International Study for Treatment of Childhood Relapsed Precursor B-cell ALL 2020 Pending
  2023-509392-17-00 5 Relapsed Acute Lymphoblastic Leukemia (ALL)
• SIOP PNET 5 medulloblastoma Pending
  2024-513724-42-00 10 Medulloblastoma
• ALASCCA-A randomized double-blind placebo-controlled study with ASA treatment in colorectal cancer patients with mutations in the PI3K signa … Pending
  2024-513778-23-00 5 Colon and rectal cancer tumor stage II-III, tumor with somatic alterat
• OSU6162 as add-on in SSRI/SNRI-resistant depression (ODEN): a double-blind, placebo-controlled evaluation of efficacy and safety Pending
  2024-513894-35-00 4 Depression
• BEACON 2: A Multi-Arm, Multi-Stage Platform Trial For Relapsed Neuroblastoma Pending
  2024-516115-24-00 9 High risk relapsed neuroblastoma (relapsed or progressed after being d
• OSU6162 in Bipolar Depression: An Open-label, Flexible Dose Study (OBID) Pending
  2024-517560-30-00 4 Bipolar depression
• ProFertil Pending
  2024-518977-32-00 5 Breast Cancer, Acute Leukemia, Lymphomas (Hodgkin and non-Hodgkin) ans
• Revumenib Treatment in Combination with FLA Chemotherapy in Paediatric Refractory/Relapsed KMT2A-r, NUP98-r or NPM1-mut Acute Myeloid Leukem … Pending
  2025-521390-14-00 4 Acute Myeloid Leukemia
• A clinical trial of ifinatamab deruxtecan in people under age 18 who have certain types of cancer (MK-9999-01D) Pending
  2025-522339-32-00 9 Neoplasm malignant
• Randomized Open Label Trial Evaluating Efficacy and Safety of Intravenous Immunoglobulin (IVIg, Privigen) as Add-on to SoC Versus SoC Alone … Pending
  2025-522756-97-00 4 COVID-19 and Severely Impaired B-cell Function
• Next generation StaR-TREC Pending
  2025-522955-25-00 6 Rectal cancer
• Tick-Borne Encephalitis (TBE) Remdesivir Efficacy Assessment Trial (TREAT) Pending
  2025-523476-23-00 4 Tick-Borne Encephalitis (TBE)
• Evaluation of hANP for prevention of acute kidney injury after cardiac surgery: A two-part randomized controlled trial with open-label exten … Pending
  2025-524069-26-00 4 Acute kidney injury (AKI) occurring in newborns and infants after card
• EMPEROR: A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen (STK-001) in Patients with Dravet Syndrome Recruiting
  2024-519555-28-00 5 2026-03-18 Dravet syndrome
• A randomized controlled phase II, double blinded trial to investigate pulmonary function after treatment with rituximab compared to placebo … Recruiting
  2024-517667-23-00 4 2025-12-17 Granulomatous Lymphocytic Interstitial Lung Disease (GLILD)
• A Study to Assess the Adverse Events, Effectiveness, and How the Drug Moves through the Body of Intravenous and Subcutaneous Injections of R … Recruiting
  2024-514695-41-00 5 2025-10-17 Ulcerative Colitis
• Long-term study to assess the safety and tolerability of adjunctive NBI-1065845 in adults with Major Depressive Disorder (MDD) Recruiting
  2024-519423-24-00 5 2025-10-07 Major Depressive Disorder
• A Phase 3, Randomized, Open-Label Study of Axatilimab Versus Best Available Therapy in Participants With Chronic Graft-Versus-Host Disease A … Recruiting
  2024-518973-32-00 5 2025-07-03 Chronic Graft-Versus-Host Disease
• Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients with FLT3-ITD Negative AML Recruiting
  2023-507936-20-00 5 2025-05-05 Acute myeloid leukemia
• International open-label phase I dose escalation study of dinutuximab beta in combination with vincristine/doxorubicin/cyclophosphamide and … Recruiting
  2024-515245-42-00 3 2025-04-24 Ewing Sarcoma
• Crohn's Disease: Pharmacokinetics, Efficacy, and Safety of Risankizumab in Pediatric Subjects with Moderately to Severely Active Crohn's Dis … Recruiting
  2022-502050-14-00 5 2024-06-04 Crohn's disease
• Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and how Drug Move … Recruiting
  2022-501599-25-00 5 2024-03-19 juvenile idiopathic arthritis

Showing 1–24 of 129 trials